OBJECTIVES: The significance of cystic fibrosis associated with early disability, the need for long-term regular treatment and follow-up and is associated with high costs. Data reflecting the socio-economic burden of cystic fibrosis in Russia is low, which dictates the need for clinical and economic studies, for example – these study. METHODS: An assessment of the burden of cystic fibrosis with the use of tobramycin inhalation solution from different manufacturers and powder inhaled tobramycin (Tobi Podhaler) for the treatment of Pseudomonas infections in patients with cystic fibrosis. The study took into account only the direct medical costs of one patient based on standards of outpatient and inpatient care for patients with cystic fibrosis. RESULTS: The burden of cystic fibrosis with the use of tobramycin powder for inhalation Tobi Podhaler with the time horizon of 10 years is reduced faster than in similar groups of patients: the point of profitability is on the 8th year of treatment when compared with tobramycin-Gobbi and a 9-year - with Bramitobom, when the use of Tobi Podhaler requires less cost to 46,372 USD and 50,138, respectively. CONCLUSIONS: Additional costs are difficult to calculate due to the fact that tobramycin solution for inhalation requires compliance with "cold chain" at all stages of the life cycle of the product: transportation, storage at the distributor and at the pharmacy, storage at home. Thus, obtained data in controlled efficacy studies of tobramycin solution in actual practice, may be significantly lower.